Treatment of inflammatory bowel disease using oral dosage forms

Details Treatment of inflammatory bowel disease using oral dosage forms Treatment of inflammatory bowel disease using oral dosage forms

1998-04-30

1999-09-07

Jordan, Kimberly

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Radical -xh acid, or anhydride, acid halide or salt thereof...

514963, A61K 3120

Patent

active

059488182

ABSTRACT:
Inflammatory bowel disease, especially Crohn's disease and ulcerative colitis, is treated by administration of an oral dosage form, containing as an active principle an omega-3 polyunsaturated acid in free acid form or as a pharmaceutically acceptable salt thereof, which releases the acid in the ileum. Preferably the oral dosage form is a gelatine capsule coated with a poly(ethylacrylate-methylmethacrylate).

REFERENCES:
patent: 5252333 (1993-10-01), Horrobin
patent: 5411988 (1995-05-01), Bockow et al.
patent: 5422115 (1995-06-01), Horrobin
patent: 5603953 (1997-02-01), Herbig et al.
patent: 5792795 (1998-08-01), Buser et al.
Rohm Pharma Gmbh brochure titled "Sustained-release coatings with Eudragit.RTM. NE 30D from aqueous dispersions" (1995).
Belluzzi, A., et al, abstract titled New Fish Oil Derivative For Preventing Clinical Relapses in Crohn's Disease: A Double Blind Placebo Controlled Randomized Trial, published Digestive Disease Weekly May 14, 1995.

Affiliated with

Also associated with

Rating

Treatment of inflammatory bowel disease using oral dosage forms does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of inflammatory bowel disease using oral dosage forms , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of inflammatory bowel disease using oral dosage forms will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1805004